Put, I like your numbers but it is as you say, "blue sky." I know NVIV has lots of potential, but what do you think the "pale blue sky" would be if, say they only got 10 to 20% of the $10 billion SCI industry and 20% of the $22 billion peripheral nerve market via hydrogel? We're still probably looking at 5 years from now. Under these pale blue parameters, where do you think the share price could get to?
I'm guessing that capturing only 10% of the market for acute and peripheral gets revenues supporting at least $65/share and this could happen before 2017. Does anybody have long horizons anymore? Geez, patients is a virtue that can make one very wealthy.